Table 4.
Univariate Analysis to Predict Objective Clinical Response
| Clinicopathological characteristics | Univariate | analysis | |
|---|---|---|---|
| Odds ratio | 95%CI | P value | |
| Age(years): | |||
| ≤50, n=24 | 1 | ||
| >50, n=35 | 1.1 | 0.4-3.3 | 0.86 |
| FIGO stage: | |||
| IIIC, n=47 | 1 | ||
| IV, n=12 | 1.1 | 0.3-4.2 | 0.92 |
| Ascites (ml): | |||
| ≤1000, n=20 | 1 | ||
| >1000, n=33 | 0.5 | 0.1-1.7 | 0.19 |
| CA125 level before NACT (IU/ml) | |||
| <500, n=27 | 1 | ||
| ≥ 500, n=30 | 0.7 | 0.2-2.0 | 0.50 |
| HE4 level before NACT (pmol) | |||
| <500, n=29 | 1 | ||
| ≥500, n=30 | 0.5 | 0.2-1.7 | 0.16 |
| Level of proteins of IGF-system in ascites before NACT (ng/mg of protein) | |||
| IGF-I | |||
| ≥2.48, n=26 | 1 | ||
| <2.48, n=27 | 3.7 | 1.0-6.7 | 0.048 |
| IGF-II | |||
| <115, n=26 | 1 | ||
| ≥115, n=27 | 1.6 | 0.4-4.8 | 0.48 |
| IGFBP-3 | |||
| <190, n=26 | 1 | ||
| ≥190, n=27 | 1.9 | 0.5-5.0 | 0.32 |
| IGFBP-4 | |||
| <97.0, n=27 | 1 | ||
| ≥97.0, n=26 | 0.9 | 0.4-2.4 | 0.57 |
| PAPP-A | |||
| Absent, n=23 | 1 | ||
| Present, n=30 | 0.6 | 0.3-1.9 | 0.44 |